000074923 001__ 74923
000074923 005__ 20200117221606.0
000074923 0247_ $$2doi$$a10.7150/thno.25149
000074923 0248_ $$2sideral$$a107259
000074923 037__ $$aART-2018-107259
000074923 041__ $$aeng
000074923 100__ $$aSanchez-Martinez, D.
000074923 245__ $$aExpansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors
000074923 260__ $$c2018
000074923 5060_ $$aAccess copy available to the general public$$fUnrestricted
000074923 5203_ $$aMonoclonal antibodies (mAbs) have significantly improved the treatment of certain cancers. However, in general mAbs alone have limited therapeutic activity. One of their main mechanisms of action is to induce antibody-dependent cell-mediated cytotoxicity (ADCC), which is mediated by natural killer (NK) cells. Unfortunately, most cancer patients have severe immune dysfunctions affecting NK activity. This can be circumvented by the injection of allogeneic, expanded NK cells, which is safe. Nevertheless, despite their strong cytolytic potential against different tumors, clinical results have been poor. Methods: We combined allogeneic NK cells and mAbs to improve cancer treatment. We generated expanded NK cells (e-NK) with strong in vitro and in vivo ADCC responses against different tumors and using different therapeutic mAbs, namely rituximab, obinutuzumab, daratumumab, cetuximab and trastuzumab. Results: Remarkably, e-NK cells can be stored frozen and, after thawing, armed with mAbs. They mediate ADCC through degranulation-dependent and -independent mechanisms. Furthermore, they overcome certain anti-apoptotic mechanisms found in leukemic cells. Conclusion: We have established a new protocol for activation/expansion of NK cells with high ADCC activity. The use of mAbs in combination with e-NK cells could potentially improve cancer treatment.
000074923 536__ $$9info:eu-repo/grantAgreement/ES/MINECO/SAF2014-54763-C2-1-R$$9info:eu-repo/grantAgreement/ES/MINECO/SAF2014-54763-C2-2-R$$9info:eu-repo/grantAgreement/ES/MINECO/SAF2017-83120-C2-1-R
000074923 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000074923 590__ $$a8.063$$b2018
000074923 591__ $$aMEDICINE, RESEARCH & EXPERIMENTAL$$b10 / 135 = 0.074$$c2018$$dQ1$$eT1
000074923 592__ $$a2.176$$b2018
000074923 593__ $$aPharmacology, Toxicology and Pharmaceutics (miscellaneous)$$c2018$$dQ1
000074923 593__ $$aMedicine (miscellaneous)$$c2018$$dQ1
000074923 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000074923 700__ $$aAllende-Vega, N.
000074923 700__ $$aOrecchioni, S.
000074923 700__ $$aTalarico, G.
000074923 700__ $$aCornillon, A.
000074923 700__ $$aVo, D.N.
000074923 700__ $$aRene, C.
000074923 700__ $$aLu, Z.Y.
000074923 700__ $$aKrzywinska, E.
000074923 700__ $$0(orcid)0000-0002-5175-8394$$aAnel, A.$$uUniversidad de Zaragoza
000074923 700__ $$aGalvez, E.M.
000074923 700__ $$0(orcid)0000-0003-0154-0730$$aPardo, J.$$uUniversidad de Zaragoza
000074923 700__ $$aRobert, B.
000074923 700__ $$aMartineau, P.
000074923 700__ $$aHicheri, Y.
000074923 700__ $$aBertolini, F.
000074923 700__ $$aCartron, G.
000074923 700__ $$aVillalba, M.
000074923 7102_ $$11008$$2566$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cÁrea Inmunología
000074923 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole.
000074923 773__ $$g8, 14 (2018), 3856-3869$$pTHERANOSTICS$$tTHERANOSTICS$$x1838-7640
000074923 8564_ $$s1791502$$uhttps://zaguan.unizar.es/record/74923/files/texto_completo.pdf$$yVersión publicada
000074923 8564_ $$s93426$$uhttps://zaguan.unizar.es/record/74923/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000074923 909CO $$ooai:zaguan.unizar.es:74923$$particulos$$pdriver
000074923 951__ $$a2020-01-17-21:46:11
000074923 980__ $$aARTICLE